Subscribe to Newsletter
Diagnostics Genetics and epigenetics

Sharing experiences from the world of easy NGS

sponsored by Thermo Scientific

Available On-Demand

October 28, 2021
5:00 p.m. CEST | 4:00 p.m. BST | 11:00 a.m. CT | 8:00 a.m. PT

It has been almost two years since the Ion Torrent™ Genexus™ Integrated Sequencer was introduced to the world. We are proud of its reception by the scientific community and the role it has played in enabling laboratories around the world to provide fast genomic profiling services, even in times of crisis.

In this webinar, we’ll introduce two European laboratories, which did not use next generation sequencing (NGS) prior to implementing Ion Torrent™ Genexus™ System.

They will share their experiences, discuss why they decided to implement the Genexus System with the Oncomine™ Precision Assay for research oncology biomarker testing in their laboratories, and how easy it really is In addition, Jon Sherlock, director of oncology product management at Thermo Fisher Scientific, will outline the company’s plans for making these products compliant with IVDR.

Learning Objectives:

  • Hear experiences from different laboratories using Ion Torrent Genexus System and Oncomine Precision Assay
  • Learn about Thermo Fisher Scientific's plan for IVDR transition in 2022
  • Have a chance to ask questions and get answers live concerning both topics

Available On-Demand

Visit our Webinar Hub

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine